Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in the 2024 Wells Fargo Securities Healthcare Conference in Boston, MA. The company's CEO and Chairman, Bobby Azamian, M.D., Ph.D., along with CFO and Chief Strategy Officer Jeff Farrow, will engage in an in-person fireside chat on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.

Tarsus, focused on addressing unmet needs in healthcare, particularly in eye care, will provide a live webcast of the presentation. Interested parties can access the webcast and additional information through the events section of the Tarsus website. A replay will be available within 48 hours and archived for a time.

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.

A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When is Tarsus Pharmaceuticals (TARS) participating in the 2024 Wells Fargo Securities Healthcare Conference?

Tarsus Pharmaceuticals (TARS) is participating in the 2024 Wells Fargo Securities Healthcare Conference on Wednesday, September 4, 2024, at 11:15 a.m. PT / 2:15 p.m. ET.

Who will represent Tarsus Pharmaceuticals (TARS) at the 2024 Wells Fargo Securities Healthcare Conference?

Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will represent Tarsus Pharmaceuticals (TARS) at the conference.

Where can I watch the Tarsus Pharmaceuticals (TARS) fireside chat from the 2024 Wells Fargo Securities Healthcare Conference?

A live webcast of the Tarsus Pharmaceuticals (TARS) fireside chat can be accessed on the events section of the Tarsus website. A replay will be available within 48 hours and archived for a time.

What is the focus of Tarsus Pharmaceuticals (TARS)?

Tarsus Pharmaceuticals (TARS) focuses on addressing unmet needs and applying proven science and new technology to revolutionize treatment for patients, starting with eye care.